Novartis appeals IP Australia decision invalidating MS drug patent
Appeals 2019-06-03 4:11 pm By Cat Fredenburgh | Melbourne
Please login to bookmark Close

Novartis has launched an appeal following a ruling by IP Australia that a proposed patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au